Immunoinformatics approach for designing a universal multiepitope vaccine against Chandipura Virus. (January 2022)

• Record Type: Journal Article
• Authors: Banik, Anik; Sinha, Shiuly; Ahmed, Sheikh Rashel; Chowdhury, Mohammed Mehadi Hassan; Mukta, Shamsunnahar; Ahmed, Nadim; Rani, Nurul Amin
• Is Part Of: Microbial pathogenesis. Volume 162(2022)
• Publication Date: 2022-01
• Subjects: Chandipura virus -- Epitope vaccine -- Immunoinformatics -- Molecular docking -- Molecular dynamics; Pathogenic microorganisms -- Periodicals; Pathology, Molecular -- Periodicals; Communicable Diseases -- microbiology -- Periodicals; Communicable Diseases -- parasitology -- Periodicals; Micro-organismes pathogènes -- Périodiques; Pathologie moléculaire -- Périodiques; Electronic journals; 616.9041
• DOI: 10.1016/j.micpath.2021.105358
• Languages: English
• ISSNs: 0882-4010

Abstract

Abstract: Chandipura vesiculovirus (CHPV) is a fast-emerging virus that causes acute encephalitis with a high death rate. Because of its extensive prevalence in African and Asian countries, this infection has become a global hazard, and there is an urgent need to create an effective and non-allergenic vaccine or appropriate treatment to combat it. A vaccine candidate is offered utilizing a computational technique in this study. To build a potential vaccine candidate, viral protein sequences were acquired from the National Center for Biotechnology Information database and evaluated with several bioinformatics techniques to identify B-cell and T-cell epitopes. V1 was shown to be superior in terms of various physicochemical qualities, as well as highly immunogenic and non-allergic. Molecular docking revealed that the CHPV vaccine construct had a greater binding affinity with human Toll-like receptors (TLR-3 and TLR-8) and that it was stable in molecular dynamics simulations. MEC-CHPV was in silico cloned in the pET28a (+) expression vector using codon optimization. The current research identifies potential antigenic epitopes that could be used as vaccine candidates to eradicate the CHPV. This in-silico development of a CHPV vaccine with multiple epitopes could open the path for future rapid laboratory tests. Graphical abstract: Image 1 Highlights: Linkers were used to link epitopes, resulting in possible vaccine candidates. Designed vaccine was non-allergic and highly antigenic. For cloning and expression, the proposed construct was modified for E. coli (K12). The vaccine-TLR3 complex was structurally stable to confer strong immune response.